MEVACOR (LOVASTATIN) APPROVAL AFTER NINE-MONTH FDA REVIEW ILLUSTRATES MERCK'S DEVELOPMENT STRENGTH; POTENTIAL U.S. POPULATION COULD EXCEED 10 MIL.